

Advancing Care for Patients With Small-Cell Lung Cancer – Clinical Brief #2

References

Tweet 2

Baize N, Monnet I, Greillier L, et al. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2020;21(9):1224-1233. doi:10.1016/s1470-2045(20)30461-7

Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. *Lancet Oncol*. 2020;21(5):645-654. doi:10.1016/s1470-2045(20)30068-1

Glossary

2L, second line

AE, adverse event

G-CSF, granulocyte colony-stimulating factor

NR, not reported

SIADH, syndrome of inappropriate antidiuretic hormone secretion

SCLC, small-cell lung cancer

w/, with